Acute Exacerbation of COPD
Conditions
Keywords
AECOPD, NIV, NAVA, ASV
Brief summary
Non invasive ventilation is the standard of care in managing patients with exacerbation of chronic obstructive pulmonary disease. However no optimal mode of NIV delivery is established; failure rates remain high, attributed to asynchrony and leak associated with NIV. Neurally adjust ventilator assist is a new mode that may improve patient ventilator interactions, improve synchrony and contribute to improved outcomes. Likewise ASV is a mode principled on the closed loop system and is associated with reduction of work associated with breathing and improved outcomes. In this randomised, non-blinded trial, we study these two modes of NIV delivery in patients of AECOPD with hypothesis being that better synchrony with NAVA may translate to better clinical outcomes.
Detailed description
Study hypothesis We hypothesize that NIV-NAVA would be superior to ASV in reducing the NIV failure rates in patients with AECOPD. In this study, we plan to compare the ASV with NAVA during NIV in patients with AECOPD. Methods All consecutive patients meeting the inclusion criteria will be screened and assessed for eligibility. Informed consent will be sought and those enrolled would be randomized to to receive NIV using either the ASV or the NIV-NAVA mode. The NIV will be delivered using a oro-nasal mask with supplemental oxygen as needed. Delivery of NAVA NAVA will be delivered using Servo-i ventilator (Maquet, Getinge Group, Sweden) with software to compensate for air leaks. NAVA initiation would involve calibration of the Edi module, placement of the nava catheter nasogastrically, verification of position and selecting appropriate nava level on the basis of required pressure support. In case a favourable response is not obtained, NAVA level will beincreased by 0.2 cm/µV until favourable response is seen (tidal volume 6-8mL/kg, respiratory rate \< 25/min) Delivery of ASV ASV will be delivered using a Galileo GOLD ventilator (Hamilton Medical, AG, Switzerland).The patients will be ventilated with an initial setting of 100%-minute volume and will be titrated in increments of 10% as per clinical parameters (respiratory rate, tidal volume). Monitoring All the patients will be monitored every 15 minutes for respiratory rate, heart rate, blood pressure, Glasgow coma score, pulse oximetry, and signs of respiratory fatigue (paradox), fit of mask and any peri-mask leak. Arterial blood gas analysis will be done at initiation of NIV and then at 1 hour, 4 hours and 24 hours and then at least once a day till primary end point is met. All the subjects will receive standard of care for acute exacerbation of COPD regardless of their allotted treatment arm. Randomization Randomization will be done by a computer-generated sequence with blocks of 8 to receive non-invasive ventilation using either the ASV or NAVA. The order of randomisation will be sealed in an opaque envelope, and opened by the physician not directly involved in the study or analysis, at the time of recruitment of patient. Statistical analysis Results will be presented in a descriptive fashion as mean ± standard deviation (SD), median (interquartile range) or number and percentage. The differences between means of continuous and categorical variables will be analysed using the Student-t-test and chi-square tests, respectively. For data that is not normally distributed the data will be analysed using non-parametric test (Mann-Whitney U).Trends in clinical (respiratory rate and mean arterial blood pressure), arterial blood gas parameters (pH, PaO2, PaCO2) and NIV parameters (peak inspiratory pressure, PEEP, tidal volume) will be analyzed using mixed model technique for repeated measures analysis of variance; the within-groups factor will be time (baseline, one, four and 24 hours), and the between-groups factor will be NIV success. A P value of \<0.05 will indicate statistical significance.
Interventions
DEVICENon invasive ventilation
Non invasive ventilation will be delivered using an oro-facial interface in both arms. NIV NAVA will be administered using Servo-i ventilator (Maquet, Getinge Group, Sweden) with software to compensate for air leaks. ASV arm will receive NIV using a Galileo GOLD ventilator (Hamilton Medical, AG, Switzerland).
Sponsors
Post Graduate Institute of Medical Education and Research, Chandigarh
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Consecutive patients enrolled would be randomized to either the NAVA arm or ASV arm. NAVA NIV NAVA will be administered using Servo-i ventilator (Maquet, Getinge Group, Sweden) ASV NIV ASV will be administered using a Galileo GOLD ventilator (Hamilton Medical, AG, Switzerland)
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
Consecutive subjects with AECOPD will be eligible for inclusion in the study if they meet all the following: (a) an acute (\<7 days) sustained worsening of any of the patient's respiratory symptoms (cough, sputum quantity or character, dyspnea) beyond the normal day-to-day variation; (b) arterial blood gas analysis showing a PaCO2 \>45 mm Hg with either pH between 7.10 and 7.35 or respiratory rate (fR) \>30 breaths/minute; and, (c) exclusion of other causes of acute breathlessness such as acute heart failure, pulmonary embolism, pneumonia, and pneumothorax.
Exclusion criteria
Patients with any one of the following criteria will be excluded from the current study: 1. Non-COPD acute hyper-capneic respiratory failure 2. Hypotension (systolic blood pressure \<90 mmHg) 3. Severe impairment of consciousness (Glasgow coma scale score \<8) 4. Inability to clear respiratory secretions 5. Abnormalities that preclude proper fit of the NIV interface (agitated or uncooperative patient, facial trauma or burns, facial surgery, or facial anatomical abnormality 6. Subjects who have an artificial airway like tracheostomy tube or T-tube 7. Contraindications for insertion of naso-/orogastric feeding tube (facial/nasal trauma, recent upper airway surgery, esophageal surgery, esophageal varices, upper gastrointestinal bleeding) 8. Unwillingness to undergo placement of nasogastric catheter 9. Known phrenic nerve lesions 10. Suspected diaphragmatic weakness 11. Patient already on home NIV therapy for chronic respiratory failure 12. Failure to provide informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of NIV failure | From initiation of NIV to either intubation or re-initiation of NIV or successful weaning | NIV failure will be considered in case of • Endotracheal intubation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 28-day mortality rate | 28 days | 28-day mortality including ICU and hospital deaths will be assessed |
| 90-day mortality rate | 90 days | 90-day mortality including deaths after discharge |
| Time to successful weaning | 28 days | Time to successful weaning will be defined as the duration between initiation of NIV and successful weaning from NIV |
| Time to NIV failure | 28 days | From initiation of NIV to either intubation or re-initiation of NIV |
| Patient assessed level of comfort using visual analogue scale | 28 days | Level of comfort will be assessed on a scale of 100 mm, 0 being very comfortable and 100 very uncomfortable |
| Average number of manipulations | 28 days | Assessed daily for 5 days or until primary outcome whichever occurs first |
| Asynchrony index | 28 days | Assessed daily until primary outcome or 5 day period, whichever occurs first |
| Physician's ease of use of the mode on visual analogue scale | Assessed every 8 hours until primary outcome | Ease of use will be recorded on a scale of 100 mm, with 0 being very easy and 100 very difficult |
Countries
India
Outcome results
None listed